Egetis Therapeutics AB (publ) (BST:P0F)
Germany
· Delayed Price · Currency is EUR 0.519
+0.006 (1.17%)
At close: Apr 27, 2026
Egetis Therapeutics AB Company Description
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally.
It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency.
The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020.
Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.
Egetis Therapeutics AB (publ)
| Country | Sweden |
| Founded | 2006 |
| Industry | Pharmaceutical Preparations |
| Employees | 42 |
| CEO | Nicklas Westerholm |
Contact Details
Address: Klara Norra Kyrkogata 26 Stockholm, 111 22 Sweden | |
| Phone | 46 86 79 72 10 |
| Website | egetis.com |
Stock Details
| Ticker Symbol | P0F |
| Exchange | Stuttgart Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nicklas Westerholm | Chief Executive Officer |
| Yilmaz Mahshid | Chief Financial Officer |
| Katayoun Welin-Berger | Chief Operating Officer |
| Karl Hard | Head of Investor Relations |